Brian Matlaga, MD
Urology · Baltimore, MDNPI 1427009539
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 97.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $66,413 and has fallen 99.8% since, to $143 in 2025. Among urology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $1024.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$97K
- Urogen Pharma, Inc.$2K
- Dornier Medtech America, Inc$335
- Calyxo, Inc.$116
- Olympus America Inc.$29
- Tolmar, Inc.$28
- plus $100 from 5 others
Across 22 payments — averaging $4090.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Calyxo, Inc.$90K
What the payments were for
- Consulting fees$57,49858%
- Speaking & faculty fees$23,75024%
- Travel & lodging$15,69716%
- Food & beverage$2,4332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 85 | $97,231 |
| Urogen Pharma, Inc. | 2 | $1,540 |
| Dornier Medtech America, Inc | 1 | $335 |
| Calyxo, Inc. | 1 | $116 |
| Olympus America Inc. | 2 | $29 |
| Tolmar, Inc. | 1 | $28 |
| 180 Medical, Inc. | 1 | $27 |
| Medtronic | 1 | $24 |
| Ambu Inc. | 1 | $21 |
| Palette Life Sciences, Inc. | 1 | $16 |
| Coloplast | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$44,711
- LithoVue$27,412
- GENERAL - THERAPIES$15,519
- JELMYTO$1,540
- CLINICAL TRIAL PRODUCT$1,200
- Dornier MedTech$335
- CVAC Aspiration System$116
How this compares
$99,378 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 13 | $1,053 |
Paid to pharmacies, not to this prescriber.
Other urology in Baltimore
- Benjamin LowentrittBaltimore$549K
- Amin HeratiBaltimore$160K
- Max KatesBaltimore$139K
- Arthur BurnettBaltimore$132K
- Aaron WeinbergBaltimore$106K
- Ronald TutroneBaltimore$89K
- Jared WinokerBaltimore$62K
- Jason LevyBaltimore$55K
- Arvin GeorgeBaltimore$46K
- Christian PavlovichBaltimore$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.